Provided by Tiger Trade Technology Pte. Ltd.

Scholar Rock Holding Corp

55.41
-0.2600-0.47%
Post-market: 61.976.56+11.84%19:59 EDT
Volume:994.40K
Turnover:55.26M
Market Cap:6.75B
PE:-16.49
High:56.94
Open:55.67
Low:54.91
Close:55.67
52wk High:61.76
52wk Low:27.07
Shares:121.79M
Float Shares:107.73M
Volume Ratio:0.82
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.3601
EPS(LYR):-3.4845
ROE:-167.77%
ROA:-58.82%
PB:26.59
PE(LYR):-15.90

Loading ...

Scholar Rock announces FDA approval of isembyld

TIPRANKS
·
12 hours ago

FDA Approves Scholar Rock’s Isembyld for Spinal Muscular Atrophy Patients Aged 2 and Older on SMN2 Therapy

Reuters
·
13 hours ago

Scholar Rock Holding Corporation - Isembyld U.S. Commercial Launch Underway; Product Available to Ship in Coming Days

THOMSON REUTERS
·
13 hours ago

Scholar Rock Announces FDA Approval of Isembyld™ (Apitegromab-Mstn), the First and Only Muscle-Targeted Treatment for Children and Adults with Spinal Muscular Atrophy (Sma)

THOMSON REUTERS
·
13 hours ago

US FDA Approves Scholar Rock's Muscle Weakness Drug

Reuters
·
14 hours ago

US FDA - Approves Isembyld for Spinal Muscular Atrophy in Patients Aged 2 Years and Older

THOMSON REUTERS
·
14 hours ago

Scholar Rock Holdings trading halted, news pending

TIPRANKS
·
14 hours ago

NASDAQ Trade Halt Halt News Pending at 05:07 Pm

Reuters
·
14 hours ago

Scholar Rock Holding Price Target Maintained with a $65.00/Share by HC Wainwright & Co.

Dow Jones
·
Sep 08

Scholar Rock Begins Phase 2 FORGE Trial of Apitegromab in Facioscapulohumeral Muscular Dystrophy

Reuters
·
Sep 02

Scholar Rock Says FDA Grants Fast Track Status for Apitegromab in FSHD

Reuters
·
Sep 02

Scholar Rock Receives FDA Fast Track Designation for Apitegromab Facioscapulohumeral Muscular Dystrophy (Fshd) Program as Participant Dosing Commences in Phase 2 Forge Trial

THOMSON REUTERS
·
Sep 02

Scholar Rock to Present at Cantor Global Healthcare Conference Fireside Chat

Reuters
·
Aug 27

Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing Pathway - Has The Bull Case Changed?

Simply Wall St.
·
Aug 24

Scholar Rock's Global Regulatory Path Further De-Risked, Wedbush Says

MT Newswires Live
·
Aug 22

Wedbush Adjusts Scholar Rock Price Target to $64 From $58, Maintains Outperform Rating

MT Newswires Live
·
Aug 22

Scholar Rock price target raised to $64 from $58 at Wedbush

TIPRANKS
·
Aug 21

Scholar Rock removes Catalent Indiana from apitegromab BLA under FDA guidance

TIPRANKS
·
Aug 21

Scholar Rock Holding Corporation - Prepared for U.S. Apitegromab Launch upon FDA Approval by Sept 30, 2026 Pdufa Date

THOMSON REUTERS
·
Aug 21

Scholar Rock Holding Corporation - Withdraws Apitegromab Maa in Europe; to Resubmit with Alternate Fill-Finish Facility

THOMSON REUTERS
·
Aug 21